Management of Statin Therapy and Triglyceride‑Lowering in Patients with NAFLD and Moderate Hypertriglyceridemia

Statin Safety in NAFLD with Mild Liver‑Enzyme Elevations

Statins are safe for patients with non‑alcoholic fatty liver disease (NAFLD) who have mildly elevated liver enzymes; they are not at increased risk for serious statin‑induced liver injury compared with patients without liver disease. Guideline recommendation (Class I, Level A). 1
The 2019 ACC/AHA cholesterol guideline states that statins are reasonable in chronic, stable liver disease—including NAFLD—when indicated for atherosclerotic cardiovascular disease (ASCVD) risk reduction. Baseline liver enzymes should be obtained, but routine serial monitoring is not required. Guideline recommendation (Class I, Level A). [2][3]
Discontinuation of statin therapy is warranted only if ALT or AST rise to ≥ 3 × upper‑limit of normal (ULN) persistently or if clinical hepatotoxicity (jaundice, right‑upper‑quadrant pain, dark urine) develops; asymptomatic mild elevations do not mandate stopping the drug. Guideline recommendation (Class I, Level A). [2][3]

A triglyceride (TG) level of 272 mg/dL represents moderate hypertriglyceridemia that remains inadequately controlled despite maximal‑dose rosuvastatin (40 mg). The 2019 ACC/AHA guideline and the 2022 ACC Expert Consensus advise adding a second lipid‑lowering agent when TG remain elevated on statin monotherapy. Guideline recommendation (Class IIa, Level A). [4][2]

Icosapent ethyl 4 g daily is recommended for patients with TG 150–499 mg/dL on statin therapy; it reduces cardiovascular events without increasing serious adverse effects. Expert consensus (Class IIa, Level A). 4
Fenofibrate is the preferred fibrate for combination with statins because gemfibrozil markedly increases statin concentrations and myopathy risk. When fenofibrate is used, rosuvastatin should not exceed 20 mg daily to minimize myopathy risk. Guideline recommendation (Class IIa, Level B). [4][5]

Re‑check the lipid panel, ALT, AST, and creatine kinase (CK) 8–12 weeks after initiating triglyceride‑lowering therapy to assess efficacy and safety. Guideline recommendation (Class I, Level A). [2][3]
If ALT/AST remain < 3 × ULN and the patient is asymptomatic, continue the current regimen; no rosuvastatin dose adjustment is needed unless transaminases rise significantly. Guideline recommendation (Class I, Level A). [2][3]
If TG fall to < 150 mg/dL and LDL‑C is at goal, maintain the combination therapy. If TG remain > 200 mg/dL, consider intensifying triglyceride therapy (e.g., higher omega‑3 dose or adding a second agent). Guideline recommendation (Class IIa, Level A). [4][2]
Routine CK or liver‑enzyme monitoring is not required in asymptomatic patients; CK should be measured only with muscle pain, weakness, or dark urine, and liver enzymes only if hepatotoxicity symptoms appear. Guideline recommendation (Class I, Level A). [2][3]

Advise 5–10 % weight loss, adoption of a Mediterranean diet, elimination of added sugars and alcohol, and ≥ 150 minutes/week of moderate‑intensity aerobic exercise; these measures improve both triglycerides and hepatic steatosis. Guideline recommendation (Class I, Level A). [6][7]

Do not discontinue statins solely because of mild LFT elevation in NAFLD; evidence shows statins are safe and may improve liver histology. Guideline recommendation (Class I, Level A). [1][2]3
Avoid gemfibrozil with any statin due to a high risk of myopathy; use fenofibrate instead. Guideline recommendation (Class IIa, Level B). [4][5]
Cardiovascular disease is the leading cause of death in NAFLD patients; aggressive lipid management is essential. Guideline recommendation (Class I, Level A). [1][7]
Educate patients to report muscle symptoms promptly; statin‑associated muscle symptoms occur in 5–20 % observationally, but true myopathy is rare. Early recognition allows timely dose adjustment or therapy change. Guideline recommendation (Class I, Level A). [2][3]